Schering-Plough Rebetron combination therapy
Schering promoted interferon alfa/ribavirin combination therapy prior to approval, agency maintains in June 12 letter to the company. FDA cites materials disseminated at the Digestive Diseases Week in New Orleans May 16-22 that resembled "a package insert for the combination therapy," letters says. Rebetron was approved by FDA on June 5 ("The Pink Sheet" June 8, p. 15)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth